NCT05154890终止1 期
A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177
Aeglea Biotherapeutics9 个研究点 分布在 3 个国家目标入组 13 人开始时间: 2021年5月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 13
- 试验地点
- 9
- 主要终点
- Incidence of treatment-emergent adverse events
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of pegtarviliase in approximately 36 subjects with homocystinuria due to CBS deficiency.
详细描述
The purpose of this Phase 1/2 study is to evaluate the safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of pegtarviliase in subjects with homocystinuria due to CBS deficiency. The study is composed of 2 parts: Part 1: a single IV (intravenous) cohort with 4 once-weekly (QW) doses of study drug and Part 2: three SC (subcutaneous) cohorts with 4 QW doses of study drug, with an optional fifth.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of homocystinuria due to CBS deficiency
- •Capable of providing signed informed consent/assent and to comply with all study related procedures
- •Is ≥12 years of age (≥18 in the US) at the time of signing the informed consent/assent
- •Plasma tHcy ≥50 µM (rounded to the nearest whole number) and documentation of previous tHcy ≥80 µM
- •Female subjects of child-bearing potential must have a negative serum pregnancy test during the screening period and a negative urine pregnancy test prior to dosing on the first day of treatment
- •If the subject (male or female) is engaging in sexual activity, he/she must be unable to become pregnant/cause pregnancy or must agree to use highly effective contraception
- •Subjects receiving pyridoxine and/or betaine must be on the same dose of the medication(s) for at least 6 weeks prior to the first administration of study drug and be willing and able to remain on a stable dose for the duration of the study. Similarly, those on prescribed dietary therapy must be on a consistent dietary regimen for at least 6 weeks prior to study drug and should maintain this regimen for the duration of the study
排除标准
- •Other medical conditions or co-morbidity(ies) that, in the opinion of the investigator, would put the subject at increased medical risk or interfere with study compliance or data interpretation (eg, severe intellectual disability that precludes completion of the required study assessments)
- •Currently participating in another therapeutic clinical study or has received any investigational agent within 30 days or 5 half-lives, whichever is longer, prior to the first dose of study drug in this study
- •Surgery requiring general anesthesia within 8 weeks prior to the first dose of study drug or planned surgery druing the treatment period
- •Active infection requiring anti-infective therapy <2 weeks prior to the first dose of study drug in this study; anti-infective therapy that completes ≥2 weeks prior to first dose of study drug is acceptable
- •Pregnant or nursing
- •Females of child-bearing potential who are using or plan to use estrogen-containing contraception during the study (unless the subject currently using estrogen-containing contraceptives is willing to switch to a non-estrogen-containing contraceptive at least 1 week before dosing and for the duration of the study) and for 30 days after the last dose
- •History of hypersensitivity to polyethylene glycol (PEG) that, in the judgment of the investigator, puts the subject at unacceptable risk for adverse events (AEs)
- •Serum creatinine level >1.5× the upper limit of normal (ULN)
- •Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin level > 2× the ULN
研究组 & 干预措施
Pegtarviliase Cohort 5
Experimental
Optional cohort for up to 12 subjects ≥12 years of age (≥18 in the US) dosing at Dose E weekly for a total of 13 doses
干预措施: Pegtarviliase SC (Drug)
Pegtarviliase Cohort 1
Experimental
Planned for 4 subjects ≥18 years of age dosing at Dose A weekly for a total of 4 doses
干预措施: Pegtarviliase IV (Drug)
Pegtarviliase Cohort 2
Experimental
Planned for 4 subjects ≥12 years of age dosing at Dose B weekly for a total of 4 doses
干预措施: Pegtarviliase SC (Drug)
Pegtarviliase Cohort 3
Experimental
Planned for 4 subjects ≥12 years of age (≥18 in the US) dosing at Dose C weekly for a total of 4 doses
干预措施: Pegtarviliase SC (Drug)
Pegtarviliase Cohort 4
Experimental
Planned for 4 subjects ≥12 years of age (≥18 in the US) dosing at Dose D weekly for a total of 4 doses
干预措施: Pegtarviliase SC (Drug)
结局指标
主要结局
Incidence of treatment-emergent adverse events
时间窗: Reporting will be from signing consent through study completion, an average of 70 days
Incidence of treatment-emergent adverse events
次要结局
- Pharmacokinetic Profile of IV pegtarviliase Cmax(At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours)
- Pharmacokinetic Profile of Subcutaneous pegtarviliase Tmax(At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours)
- Pharmacokinetic Profile of Subcutaneous pegtarviliase T 1/2(At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours)
- Time course of tHcy change after pegtarviliase administration and reversibility upon follow up post dosing(Weekly, baseline through study completion, up to 12 weeks)
- Pharmacokinetic Profile of IV pegtarviliase AUC(At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours)
- Pharmacokinetic Profile of IV pegtarviliase Tmax(At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours)
- Pharmacokinetic Profile of IV pegtarviliase T1/2(At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours)
- Pharmacokinetic Profile of Subcutaneous pegtarviliase Cmax(At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours)
- Pharmacokinetic Profile of Subcutaneous pegtarviliase AUC(At pre-dose, 1hour, 6hours, 24hours, 48hours, 72hours, 96hours and 120hours)
- Changes in total plasma homocysteine after treatment with pegtarviliase(At Visit Day 29)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
1 期
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis CChronic Hepatitis C InfectionGenotype 1NCT01194037HanAll BioPharma Co., Ltd.30
已完成
3 期
Long-Term Safety and Efficacy Study of Peginterferon Beta-1aRelapsing Multiple SclerosisNCT01332019Biogen1,077
进行中（未招募）
1 期
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Lymphoma, B-CellSmall Lymphocytic LymphomaWaldenstrom MacroglobulinemiaDiffuse Large B Cell LymphomaRichter's TransformationMarginal Zone LymphomaChronic Lymphocytic LeukemiaFollicular LymphomaMantle Cell LymphomaNCT03162536ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)190
已完成
1 期
A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult SubjectsHealthyNCT00956956Pfizer36
已完成
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)Healthy VolunteersGeneralized Anxiety Disorder (GAD)Bipolar Disorder (BPD)NCT06024239AbbVie72